Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Limited sampling models for amonafide (NSC 308847) pharmacokinetics.

M J Ratain1, A E Staubus, R L Schilsky

  • 1Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois.

Cancer Research
|July 15, 1988
PubMed
Summary

The limited sampling model (LSM) accurately estimates drug exposure (AUC) using just two blood samples. This pharmacokinetic tool simplifies drug monitoring for amonafide treatment in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

ESMO open·2025
Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Nature·2019
Same author

Guideposts on the journey to value.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

Clinical pharmacology and therapeutics·2017
Same author

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Clinical pharmacology and therapeutics·2017

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism and Disposition

Background:

  • The Area Under the Curve (AUC) is crucial for assessing drug exposure.
  • Estimating AUC typically requires multiple blood samples, which can be burdensome in clinical settings.

Purpose of the Study:

  • To develop and validate a Limited Sampling Model (LSM) for estimating amonafide's AUC.
  • To assess the feasibility of using LSM for population pharmacokinetic studies.

Main Methods:

  • Simulated pharmacokinetic profiles for 23 patients receiving amonafide (250 mg/m2 over 1h).
  • Developed five LSMs using a training set of 15 patients.
  • Selected and validated an optimal LSM using a test set of 7 patients.

Main Results:

  • The optimal LSM achieved a high correlation (r=0.92-0.98) with actual AUC values.

Related Experiment Videos

  • The validated model demonstrated a 15.8% relative root mean square predictive error, deemed clinically acceptable.
  • The derived LSM formula incorporates 45-minute and 24-hour plasma concentrations and dose.

    • Conclusions:

    • The Limited Sampling Model (LSM) is a robust method for estimating drug exposure (AUC) from minimal plasma samples.
    • LSM can simplify pharmacokinetic assessments in large patient populations and support clinical trials.